# Brigatinib (Alunbrig)

Source: https://ourhealthnetwork.com/drugs/brigatinib
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Brigatinib?

Brigatinib (brand name: Alunbrig) is a kinase inhibitor. It is prescribed to treat carcinoma, non-small-cell lung.

## Brand names

Alunbrig

## Indications

Brigatinib is prescribed for the treatment of carcinoma and non-small-cell lung.

## Conditions treated

- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Non-Small-Cell Lung](https://ourhealthnetwork.com/conditions/non-small-cell-lung)

## Mechanism of action

Brigatinib is a tyrosine kinase inhibitor (TKI) with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations. Brigatinib inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, a

## Drug classification

- Established Pharmacologic Class: Kinase Inhibitor [EPC]
- Mechanism of Action class: Tyrosine Kinase Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

and asthenia, and pneumonia, asian, c adenocarcinoma histology, dyspnea, female, never smoker, of patients and included pneumonia

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)